<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05619120</url>
  </required_header>
  <id_info>
    <org_study_id>XJTU1AF2021CRF-001</org_study_id>
    <nct_id>NCT05619120</nct_id>
  </id_info>
  <brief_title>The Effect of Late Na Current Blocker Mexiletine on Giant T-wave Electrical Alternans(STOP-TWA)</brief_title>
  <official_title>Potential of Late Na Current Blocker Mexilate on Giant T-wave Electrical Alternans and Subsequent Ventricular Arrhythmias: a Multicenter, Randomized, Prospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>First Affiliated Hospital Xi'an Jiaotong University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>First Affiliated Hospital Xi'an Jiaotong University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The electrocardiogram is one of the most basic tests for cardiovascular disease. T wave&#xD;
      alternans (TWA), which reflects abnormal ventricular repolarization, can easily trigger&#xD;
      ventricular tachycardia (VT) and ventricular fibrillation (VF), which are important warning&#xD;
      clues for sudden cardiac death (SCD). The late sodium current (INaL) is an important&#xD;
      component of the frequency-dependent regulation of cardiac repolarization, and various causes&#xD;
      of delayed repolarization can increase INaL. Our study on long QT syndrome (LQTS) found that&#xD;
      INaL abnormalities can lead to abnormal myocardial repolarization, producing a giant TWA that&#xD;
      triggers VT and VF. VT and VF, and INaL inhibition by the INaL blocker mexilate can terminate&#xD;
      this process. This suggests that pharmacological blockade of INaL may be a potential target&#xD;
      for the prevention of SCD by ameliorating the different causes of giant TWA and its&#xD;
      triggering ventricular arrhythmic events. In this study, we propose to randomize patients&#xD;
      with VT/VF triggered by giant TWA to conventional treatment and conventional treatment adds&#xD;
      mexiletine treatment to compare the effects of the two treatment regimens on giant TWA and&#xD;
      its triggered nonsustained VT, sustained VT, and VF; at the same time, we will compare the&#xD;
      effects of mexiletine on giant TWA and its triggered ventricular arrhythmias of various&#xD;
      etiologies by intra-group control before and after treatment. The safety and efficacy of the&#xD;
      treatment of TWA and its triggered ventricular arrhythmias are compared.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2023</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The occurrence of macroscopic TWA</measure>
    <time_frame>within 0 hour after administration.</time_frame>
    <description>Macroscopic TWA occurring on conventional ECG (12-lead ECG, telemetry ECG, or holter ECG) with visually identifiable TWA Diagnosis confirmed by at least 3 leading ECG specialists.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The occurrence of macroscopic TWA</measure>
    <time_frame>within 24 hours after administration.</time_frame>
    <description>Macroscopic TWA occurring on conventional ECG (12-lead ECG, telemetry ECG, or holter ECG) with visually identifiable TWA Diagnosis confirmed by at least 3 leading ECG specialists.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The occurrence of macroscopic TWA</measure>
    <time_frame>within 48 hours after administration.</time_frame>
    <description>Macroscopic TWA occurring on conventional ECG (12-lead ECG, telemetry ECG, or holter ECG) with visually identifiable TWA Diagnosis confirmed by at least 3 leading ECG specialists.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The occurrence of macroscopic TWA</measure>
    <time_frame>within 72 hours after administration.</time_frame>
    <description>Macroscopic TWA occurring on conventional ECG (12-lead ECG, telemetry ECG, or holter ECG) with visually identifiable TWA Diagnosis confirmed by at least 3 leading ECG specialists.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The occurrence of macroscopic TWA</measure>
    <time_frame>within 96 hours after administration.</time_frame>
    <description>Macroscopic TWA occurring on conventional ECG (12-lead ECG, telemetry ECG, or holter ECG) with visually identifiable TWA Diagnosis confirmed by at least 3 leading ECG specialists.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The occurrence of macroscopic TWA</measure>
    <time_frame>within 120 hours after administration.</time_frame>
    <description>Macroscopic TWA occurring on conventional ECG (12-lead ECG, telemetry ECG, or holter ECG) with visually identifiable TWA Diagnosis confirmed by at least 3 leading ECG specialists.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The occurrence of macroscopic TWA</measure>
    <time_frame>within 144 hours after administration.</time_frame>
    <description>Macroscopic TWA occurring on conventional ECG (12-lead ECG, telemetry ECG, or holter ECG) with visually identifiable TWA Diagnosis confirmed by at least 3 leading ECG specialists.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The occurrence of macroscopic TWA</measure>
    <time_frame>within 168 hours after administration.</time_frame>
    <description>Macroscopic TWA occurring on conventional ECG (12-lead ECG, telemetry ECG, or holter ECG) with visually identifiable TWA Diagnosis confirmed by at least 3 leading ECG specialists.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Termination of ventricular arrhythmias</measure>
    <time_frame>within 0 hour after administration.</time_frame>
    <description>Termination of Non-sustained ventricular tachycardia/sustained ventricular tachycardia/ventricular fibrillation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Termination of ventricular arrhythmias</measure>
    <time_frame>within 24 hours after administration.</time_frame>
    <description>Termination of Non-sustained ventricular tachycardia/sustained ventricular tachycardia/ventricular fibrillation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Termination of ventricular arrhythmias</measure>
    <time_frame>within 48 hours after administration.</time_frame>
    <description>Termination of Non-sustained ventricular tachycardia/sustained ventricular tachycardia/ventricular fibrillation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Termination of ventricular arrhythmias</measure>
    <time_frame>within 72 hours after administration.</time_frame>
    <description>Termination of Non-sustained ventricular tachycardia/sustained ventricular tachycardia/ventricular fibrillation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Termination of ventricular arrhythmias</measure>
    <time_frame>within 96 hours after administration.</time_frame>
    <description>Termination of Non-sustained ventricular tachycardia/sustained ventricular tachycardia/ventricular fibrillation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Termination of ventricular arrhythmias</measure>
    <time_frame>within 120 hours after administration.</time_frame>
    <description>Termination of Non-sustained ventricular tachycardia/sustained ventricular tachycardia/ventricular fibrillation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Termination of ventricular arrhythmias</measure>
    <time_frame>within 144 hours after administration.</time_frame>
    <description>Termination of Non-sustained ventricular tachycardia/sustained ventricular tachycardia/ventricular fibrillation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Termination of ventricular arrhythmias</measure>
    <time_frame>within 168 hours after administration.</time_frame>
    <description>Termination of Non-sustained ventricular tachycardia/sustained ventricular tachycardia/ventricular fibrillation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The related indicators of repolarization.</measure>
    <time_frame>0 day, 1 day, 2 days, 3 days, 4 days, 5 days, 6 days and 7 days after administration.</time_frame>
    <description>QT, Tp-e, QT/Tp-e, TDR, QRS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>0 day, 1 day, 2 days, 3 days, 4 days, 5 days, 6 days and 7 days after administration.</time_frame>
    <description>Comparison between two treatment groups due to the effect of ventricular arrhythmia episodes on the duration of hospitalization ( days) in patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of refractory cases</measure>
    <time_frame>0 day, 1 day, 2 days, 3 days, 4 days, 5 days, 6 days and 7 days after administration.</time_frame>
    <description>The number of cases in the group requiring ICD for ventricular arrhythmia episodes was used as an indicator.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Giant T-wave Electrical Alternans</condition>
  <arm_group>
    <arm_group_label>Giant T-wave electrical alternans conventional plus mexiletine therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>It is proposed that patients presenting with giant TWA-triggered VT/VF patients to be randomized to conventional treatment and conventional plus mexiletine treatment, respectively.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Giant T-wave electrical alternans conventional therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Conventional treatment in the control group according to the guidelines for the management of ventricular arrhythmias (2017 AHA/ACC/HRS)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mexiletine</intervention_name>
    <description>Mexiletine (150mg, bid, po) is given to patients who have been divided into Mexiletine group.</description>
    <arm_group_label>Giant T-wave electrical alternans conventional plus mexiletine therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Conventional therapy</intervention_name>
    <description>Treatment according to the guidelines for the management of ventricular arrhythmias (2017 AHA/ACC/HRS)</description>
    <arm_group_label>Giant T-wave electrical alternans conventional plus mexiletine therapy</arm_group_label>
    <arm_group_label>Giant T-wave electrical alternans conventional therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Clinical diagnosis of macroscopic TWA&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The patients who do not agree to participate in the study,&#xD;
&#xD;
          -  Patients with acute coronary syndrome or with progressive myocardial ischemia&#xD;
             according to clinical manifestations, electrocardiogram or myocardial biochemical&#xD;
             markers;&#xD;
&#xD;
          -  Those who have used other class I antiarrhythmic drugs or who are contraindicated by&#xD;
             mexiletine.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guoliang Li</last_name>
    <role>Study Director</role>
    <affiliation>First Affiliated Hospital of Xi'an Jiaotong University, China</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Guoliang Li</last_name>
    <phone>0086-13759982523</phone>
    <phone_ext>13759982523</phone_ext>
    <email>13759982523@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sun</last_name>
    <phone>0086-13759982523</phone>
    <phone_ext>13759982523</phone_ext>
    <email>13759982523@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>First Affiliated Hospital of Xian Jiantong University</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710061</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guoliang Li</last_name>
      <phone>008613759982523</phone>
      <email>liguoliang_med@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2023</verification_date>
  <study_first_submitted>November 24, 2019</study_first_submitted>
  <study_first_submitted_qc>November 8, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 16, 2022</study_first_posted>
  <last_update_submitted>May 6, 2023</last_update_submitted>
  <last_update_submitted_qc>May 6, 2023</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 9, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mexiletine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

